Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 377Gynecologic 26Thoracic 19Gastrointestinal 14Genitourinary 12Tumor-Agnostic 10Other solid neoplasm 9Head & Neck 6Sarcoma 5Endocrine 4Lymphoid 3Other neoplasm 2Dermatologic 2CNS 2

Conditions

Multiple Endocrine Neoplasia Type 1 4Breast Neoplasms 3Neoplasms 2Neoplasms by Site 1Neoplasm Metastasis 1Hyperglycemia 1Breast Diseases 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Fulvestrant × Endocrine × Clear all
NCT05631795 2026-04-07

ALPINIST

Novartis

Phase 4 Completed
40 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

NCT04300790 2025-07-29

METALLICA

MedSIR

Phase 2 Completed
69 enrolled
BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed
726 enrolled 17 charts 1 FDA
BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡